SEC Form 4 · accession 0000899243-16-013609
PROTEOSTASIS THERAPEUTICS, INC. · PTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Franklin M Berger
Director
Period of report
Feb 17, 2016
Accepted (ET)
Feb 17, 2016 · 6:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001445283
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 17, 2016 | C | 71,932 | — | A | 71,932 | D | |
| Common StockF2 | Feb 17, 2016 | P | 25,000 | $8.00 | A | 96,932 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Redeemable Preferred StockF3 | — | Feb 17, 2016 | C | 777,604 | D | — | — | Common Stock | 71,932 | 0 | D |
Explanation of responses
- F1This transaction represents the total number of shares of Issuer Common Stock received upon the conversion of the Issuer's Series B Convertible Redeemable Preferred Stock (the "Series B Shares").
- F2These securities were purchased in the initial public offering of the Issuer.
- F3The Series B Shares automatically converted into Issuer Common Stock on a 10.8102-to-1 basis upon the closing of the initial public offering of the Issuer without payment or further consideration. The Series B Shares were convertible at any time at the election of the Reporting Person and had no expiration date.